Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2579-2583

  Heeren, Pierre A M ^a   Kloppenberg, Frank W H ^a   Hollema, Harry ^a   Mulder, Nanno H ^a   Nap, Raoul E ^a   Plukker, John Th M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptotic markers; Chemotherapy response; Esophageal carcinoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; METHOTREXATE; PROTEIN P21; PROTEIN P53; TENIPOSIDE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; ESOPHAGUS CARCINOMA; ESOPHAGUS SURGERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NETHERLANDS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444320783     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Muller JM, Erasmi H, Stelzner M et al: Surgical therapy of oesophageal carcinoma. Br J Surg 77: 845-57, 1990.
2. Swanson SJ, Batirel HF, Bueno R et al: Transthoracic esophagectomy with radical mediastinal and abominal lymph node dissection and cervical esophagogastrpstomy for esophageal carcinoma. Ann Thorac Surg 72: 1918-25, 2001.
3. Walsh TN, Noonan N, Hollywood D et al: A comparison of multimodality therapy and surgery for esophageal carcinoma. N Engl J Med 335: 462-510, 1996.
4. Forastiere AA, Heitmiller RF, Lee DJ et al: Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 3: 144-52, 1997.
5. Kelsen DP, Ginsberg R, Pajak TF et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: 1979-84, 1998.
6. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-33, 2002.
7. Bosset JF, Gignoux M, Triboulet JP et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 161-7, 1977.
8. Urba SG, Orringer MB, Turrisi A et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-13, 2001.
9. Heath EI, Burtness BA, Heitmiller RF et al: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18: 868-76, 2000.
10. Kerr JFR, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implication in tissue kinetics. Br J Cancer 26: 239-57, 1972.
11. Koshiji M, Adachi Y, Taketani S et al: Mechanism underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma. Biochem Biophys Res Commun 52: 376-81, 1997.
12. Kastan MB, Onyekwere O, Sidransky D et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-11, 1991.
13. Namba H, Hara T, Tukazaki T, Migita K et al: Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 55: 2075-80, 1995.
14. Youssef EM, Matsuda T, Takada N et al: Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 76: 358-366, 1995.
15. Okuno Y, Nishimura Y, Kashu I et al: Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of esophageal squamous cell carcinomas. Br J Cancer 80: 387-395, 1999.
16. Horii N, Nishimura Y, Okuno Y et al: Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas. Int J Radiation Oncol Biol Phys 49: 527-532, 2001.
17. Brucher BL, Weber W, Bauer M et al: Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233: 320-1, 2001.
18. Flamen P, Van Cutsem E, Lerut A et al: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-8, 2002.
19. Plukker JT, Sleijfer DT, Verschueren RC et al: Neoadjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower esophagus: a phase II study. Anticancer Res 15: 2357-61, 1995.
20. Plukker JT, Mulder NH, Sleijfer DT et al: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: a phase II study with methotrexate and 5-fluorouracil. Br J Surg 78: 955-8, 1991.
21. Kok TC, Lanschot JV, Siersema PD et al: Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomized controlled trial. Proc Asco 16: 277, 1997.
22. Hirai T, Kuwahara M, Yoshida K et al: The prognostic significance of p53, p21 (Waf1/Cip1), and cyclin D1 protein expression in esophageal cancer patients. Anticancer Res 19: 4587-92, 1999.
23. Parenti AR, Rugge M, Frizzera E et al: P53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol 19: 1418-22, 1995.
24. Wagata T, Shibagaki I, Imamura M et al: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinoma. Cancer Res 3: 1195-1200, 1997.
25. Muro K, Ohtsu A, Boku N et al: Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol 26: 65-9, 1996.
26. Lam KY, Law S, Ma LT, Ong SK et al: Preoperative chemotherapy for squamous cell carcinoma of the esophagus: do histological assessment and p53 overexpression predict chemoresponsiveness? Eur J Cancer 33: 1221-5, 1997.
27. Shimada Y, Watanabe G, Yamasaki et al: Histological response of cisplatin predicts patients' survival in esophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer 36: 987-93, 2000.
28. Shimoyama S, Konishi T, Kawahara M et al: Expression and alteration of p53 and p21 influence the sensitivity of chemoradiation therapy for esophageal cancer. Hepatogastroenterology 45: 1497-1504, 1998.
29. Garzetti GG, Ciavattini A, Luccarini G et al: Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. Eur J Obstet Gynecol Reprod Biol 63: 31-6, 1995.